Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.

[1]  H. McElroy,et al.  Risk factors for Pseudomonas aeruginosa infections in Asia-Pacific and consequences of inappropriate initial antimicrobial therapy: A systematic literature review and meta-analysis. , 2018, Journal of global antimicrobial resistance.

[2]  A. Oliver,et al.  Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa , 2018, The Journal of antimicrobial chemotherapy.

[3]  M. Castanheira,et al.  Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility. , 2017, Microbial drug resistance.

[4]  R. Humphries,et al.  Performance of Ceftolozane-Tazobactam Etest, MIC Test Strips, and Disk Diffusion Compared to Reference Broth Microdilution for β-Lactam-Resistant Pseudomonas aeruginosa Isolates , 2017, Journal of Clinical Microbiology.

[5]  B. Kreiswirth,et al.  Emergence of Ceftolozane-Tazobactam-Resistant Pseudomonas aeruginosa during Treatment Is Mediated by a Single AmpC Structural Mutation , 2017, Antimicrobial Agents and Chemotherapy.

[6]  G. Pankey,et al.  Colistin and Polymyxin B Minimal Inhibitory Concentrations Determined by Etest Found Unreliable for Gram-Negative Bacilli. , 2017, The Ochsner journal.

[7]  M. Castanheira,et al.  Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013-2015). , 2017, Journal of global antimicrobial resistance.

[8]  R. Bonomo,et al.  Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  B. F. Araújo,et al.  Molecular epidemiological survey of bacteremia by multidrug resistant Pseudomonas aeruginosa: the relevance of intrinsic resistance mechanisms , 2017, PloS one.

[10]  M. Hackel,et al.  Resistance among Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Latin American countries: SMART 2013–2015 , 2017, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[11]  N Klein,et al.  Risk in the "Red Zone": outcomes for children admitted to Ebola holding units in Sierra Leone without Ebola virus disease. , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  J. Torre-Cisneros,et al.  Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections , 2016, Antimicrobial Agents and Chemotherapy.

[13]  J. Kirby,et al.  Improved Accuracy of Cefepime Susceptibility Testing for Extended-Spectrum-Beta-Lactamase-Producing Enterobacteriaceae with an On-Demand Digital Dispensing Method , 2016, Journal of Clinical Microbiology.

[14]  M. Veve,et al.  Comparison of Etest to Broth Microdilution for Testing of Susceptibility of Pseudomonas aeruginosa to Ceftolozane-Tazobactam , 2016, Journal of Clinical Microbiology.

[15]  D. Nicolau,et al.  Successful Treatment of Multi-Drug Resistant Pseudomonas aeruginosa Bacteremia with the Recommended Renally Adjusted Ceftolozane/Tazobactam Regimen , 2016, Infectious Diseases and Therapy.

[16]  M. E. Zowalaty,et al.  Effectiveness of Antipseudomonal Antibiotics and Mechanisms of Multidrug Resistance in Pseudomonas aeruginosa , 2016, Polish journal of microbiology.

[17]  Ronald N. Jones,et al.  Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). , 2014, The Journal of antimicrobial chemotherapy.

[18]  Ronald N. Jones,et al.  Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012) , 2013, Antimicrobial Agents and Chemotherapy.

[19]  J. Karlowsky,et al.  Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli , 2013, Drugs.

[20]  A. Oliver,et al.  Pan-β-Lactam Resistance Development in Pseudomonas aeruginosa Clinical Strains: Molecular Mechanisms, Penicillin-Binding Protein Profiles, and Binding Affinities , 2012, Antimicrobial Agents and Chemotherapy.

[21]  M. Maciá,et al.  Overexpression of AmpC and Efflux Pumps in Pseudomonas aeruginosa Isolates from Bloodstream Infections: Prevalence and Impact on Resistance in a Spanish Multicenter Study , 2011, Antimicrobial Agents and Chemotherapy.

[22]  A. Oliver,et al.  Activity of a New Cephalosporin, CXA-101 (FR264205), against β-Lactam-Resistant Pseudomonas aeruginosa Mutants Selected In Vitro and after Antipseudomonal Treatment of Intensive Care Unit Patients , 2010, Antimicrobial Agents and Chemotherapy.

[23]  K. Ko,et al.  Inappropriate initial antimicrobial therapy as a risk factor for mortality in patients with community-onset Pseudomonas aeruginosa bacteraemia , 2008, European Journal of Clinical Microbiology & Infectious Diseases.

[24]  E. Bingen,et al.  Pseudomonas aeruginosa May Accumulate Drug Resistance Mechanisms without Losing Its Ability To Cause Bloodstream Infections , 2007, Antimicrobial Agents and Chemotherapy.

[25]  R. Bonomo,et al.  Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  Stephan Harbarth,et al.  Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. , 2003, The American journal of medicine.